KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fulgent Genetics (FLGT) Equity Income (2017 - 2020)

Fulgent Genetics' Equity Income history spans 4 years, with the latest figure at $143000.0 for Q4 2020.

  • For Q4 2020, Equity Income rose 182.18% year-over-year to $143000.0; the TTM value through Dec 2020 reached -$488000.0, up 37.19%, while the annual FY2020 figure was -$488000.0, 37.19% up from the prior year.
  • Equity Income for Q4 2020 was $143000.0 at Fulgent Genetics, up from -$189000.0 in the prior quarter.
  • Across five years, Equity Income topped out at $143000.0 in Q4 2020 and bottomed at -$279000.0 in Q1 2019.
  • The 4-year median for Equity Income is -$189000.0 (2020), against an average of -$172538.5.
  • The largest annual shift saw Equity Income crashed 134.29% in 2018 before it soared 182.18% in 2020.
  • A 4-year view of Equity Income shows it stood at -$172000.0 in 2017, then dropped by 22.09% to -$210000.0 in 2018, then increased by 17.14% to -$174000.0 in 2019, then skyrocketed by 182.18% to $143000.0 in 2020.
  • Per Business Quant, the three most recent readings for FLGT's Equity Income are $143000.0 (Q4 2020), -$189000.0 (Q3 2020), and -$193000.0 (Q2 2020).